GlaxoSmithKline Pharmaceuticals Limited (NSE:GLAXO)

Market Cap	437.81B +30.4%
Revenue (ttm)	38.01B +2.6%
Net Income	10.21B +18.8%
EPS	60.26 +18.8%
Shares Out	n/a
PE Ratio	42.88
Forward PE	38.65
Dividend	42.00 (1.62%)
Ex-Dividend Date	May 30, 2025

Volume	44,735
Average Volume	84,005
Open	2,584.00
Previous Close	2,583.80
Day's Range	2,584.00 - 2,617.00
52-Week Range	2,220.30 - 3,515.70
Beta	-0.05
RSI	58.13
Earnings Date	Feb 9, 2026

About NSE:GLAXO

GlaxoSmithKline Pharmaceuticals Limited manufactures, distributes, and trades in pharmaceuticals in India and internationally. The company offers vaccines, such as Infanrix Hexa for vaccination of infants against diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis, and disease caused by Haemophilus influenzae type B; Synflorix for active immunization of infants against pneumococcal diseases and acute otitis media; Havrix for active immunization against disease caused by Hepatitis A virus; Menveo to prevent invasive meningococcal disease;...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1924
• Employees: 3,113
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: GLAXO

Financial Performance

In fiscal year 2025, NSE:GLAXO's revenue was 37.49 billion, an increase of 8.56% compared to the previous year's 34.54 billion. Earnings were 9.28 billion, an increase of 57.23%.